181 related articles for article (PubMed ID: 27244897)
21. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
22. Neurogenic and neuro-protective potential of a novel subpopulation of peripheral blood-derived CD133+ ABCG2+CXCR4+ mesenchymal stem cells: development of autologous cell-based therapeutics for traumatic brain injury.
Nichols JE; Niles JA; DeWitt D; Prough D; Parsley M; Vega S; Cantu A; Lee E; Cortiella J
Stem Cell Res Ther; 2013 Jan; 4(1):3. PubMed ID: 23290300
[TBL] [Abstract][Full Text] [Related]
23. [Are CD133 and CD271 useful in positive selection to enrich umbilical cord blood mesenchymal stem cells?].
Liu QH; Ge J; Liu KY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1286-91. PubMed ID: 21129278
[TBL] [Abstract][Full Text] [Related]
24. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity.
Tondreau T; Meuleman N; Delforge A; Dejeneffe M; Leroy R; Massy M; Mortier C; Bron D; Lagneaux L
Stem Cells; 2005 Sep; 23(8):1105-12. PubMed ID: 15955825
[TBL] [Abstract][Full Text] [Related]
25. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
26. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
27. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
Chang CH; Liu WT; Hung HC; Gean CY; Tsai HM; Su CL; Gean PW
BMC Cancer; 2017 Dec; 17(1):905. PubMed ID: 29284440
[TBL] [Abstract][Full Text] [Related]
28. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
29. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
Kanwal R; Shukla S; Walker E; Gupta S
Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627
[TBL] [Abstract][Full Text] [Related]
30. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
Jamal M; Rath BH; Tsang PS; Camphausen K; Tofilon PJ
Neoplasia; 2012 Feb; 14(2):150-8. PubMed ID: 22431923
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor-β and stem cell markers are highly expressed around necrotic areas in glioblastoma.
Iwadate Y; Matsutani T; Hirono S; Shinozaki N; Saeki N
J Neurooncol; 2016 Aug; 129(1):101-7. PubMed ID: 27193555
[TBL] [Abstract][Full Text] [Related]
32. Isolation, cultivation and characterization of CD133+ stem cells from human glioblastoma.
Pavon LF; Marti LC; Sibov TT; Miyaki LA; Malheiros SM; Mamani JB; Brandt RA; Ribas GC; Pagura JR; Joaquim MA; Feres Junior H; Gamarra LF
Einstein (Sao Paulo); 2012; 10(2):197-202. PubMed ID: 23052455
[TBL] [Abstract][Full Text] [Related]
33. In vitro characterization of CD133
Nair RM; Balla MM; Khan I; Kalathur RKR; Kondaiah P; Vemuganti GK
BMC Cancer; 2017 Nov; 17(1):779. PubMed ID: 29162051
[TBL] [Abstract][Full Text] [Related]
34. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
35. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
[TBL] [Abstract][Full Text] [Related]
36. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
37. Molecular determinants of the interaction between glioblastoma CD133
Shevchenko V; Arnotskaya N; Pak O; Sharma A; Sharma HS; Khotimchenko Y; Bryukhovetskiy A; Bryukhovetskiy I
Int Rev Neurobiol; 2020; 151():155-169. PubMed ID: 32448605
[TBL] [Abstract][Full Text] [Related]
38. The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood.
Zeddou M; Briquet A; Relic B; Josse C; Malaise MG; Gothot A; Lechanteur C; Beguin Y
Cell Biol Int; 2010 Jul; 34(7):693-701. PubMed ID: 20187873
[TBL] [Abstract][Full Text] [Related]
39. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC
Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216
[TBL] [Abstract][Full Text] [Related]
40. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
